The European social impact fund, Impact Partners, has recently made a significant investment in the Danish company Chromaviso. Chromaviso is known for its circadian lighting solutions for hospitals and nursing homes in Scandinavia. This investment aims to unlock the potential for even more patients and individuals with dementia to benefit from this innovative treatment option, which has already demonstrated significant positive effects on mental and physical health.
With an investment of 37 million DKK, the path is paved for the dissemination of Danish Chromaviso light to individuals with dementia, psychiatric patients, and hospital patients.
— We are on the threshold of a new era in the use of circadian lighting in the healthcare and nursing sector, and we believe that Chromaviso will continue to be the natural leader in this field. Their solutions are backed by clinical studies and are based on highly specialized knowledge that they have acquired through years of work and innovative projects, explains Ulrik Fonsmark Andreasen, Managing Director of Impact Partners Nordic.
Collaboration serves as the foundation for investment
Impact Partners is currently raising their sixth social impact fund, which aims to invest in small and medium-sized companies that help vulnerable citizens. The fund was established in early 2021 in Denmark, and the investment in Chromaviso will be their first direct investment in a Danish company.
— Chromaviso's mission aligns with ours: To improve the lives of vulnerable citizens. Their lighting technology enhances the well-being of dementia patients, patients in psychiatric departments, and hospitalized individuals. It treats depression, anxiety, and fatigue. Additionally, their light helps reduce stress and improve concentration among staff, particularly during laparoscopic surgery - and it has no side effects. It is a breakthrough in mental health, and we are excited to be part of the journey, says Ulrik Fonsmark Andreasen.
More than 500,000 patients and dementia sufferers in Scandinavia are treated in Chromaviso's light annually. Their solutions are being used by an increasing number of treatment facilities, most recently at the new Neurocenter at Rigshospitalet. But this is just the beginning, according to co-founder and CEO Anders Kryger.
— The interest in incorporating lighting into large construction projects has significantly increased in recent years. The new hospitals and nursing homes want the environment to contribute to the patient's healing process and the working environment. Our solution is prioritized as a safe choice because it is based on both evidence and experience. At the same time, we are seeing customers who have had our circadian lighting for several years coming back with a desire to expand the solution to larger areas or more departments, he explains.
The market is ready
Chromaviso has currently implemented lighting in over 2,500 projects across 130 hospitals and nursing homes throughout the Nordic region.
— The market is ready, and we are ready. With Impact on board, we now have the opportunity to accelerate the rollout in the Nordic region while continuing our long-term strategy of setting the highest standards for knowledge, evidence, and technology. More people should benefit from the beneficial effects of light on health and quality of life, and our ambition is for light to become a permanent part of treatment environments - even outside the Nordic region, concludes Anders Kryger.
The investment from Impact Partners aims to ensure the realization of Chromaviso's ambition to quintuple their revenue in the healthcare niche market in the Nordic region and eventually in Europe. The investment will be used to scale the business, including new innovation projects, increased digitization, and an intensification and internationalization of sales efforts.